Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.63 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorescein SCHEMBL9221862 | 0.84 | FTO (0.77) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL31729031 | 0.83 | FTO (0.61) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL30402787 | 0.83 | FTO (0.61) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL29589246 | 0.81 | FTO (0.66) | FTOMAPTMEN1KMT2AHPGD | |
| Fluorescein SCHEMBL27395251 | 0.81 | FTO (0.82) | FTOMAPTMEN1KMT2AHPGD | |
| Fluorescein SCHEMBL27504008 | 0.81 | FTO (0.82) | FTOMAPTMEN1KMT2AHPGD | |
| Fluorescein SCHEMBL27157739 | 0.80 | FTO (0.92) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL5275280 | 0.80 | HPGD (0.54) | FTOMAPTMEN1KMT2AHPGD | |
| Fluorescein SCHEMBL3293893 | 0.80 | FTO (0.97) | FTOMAPTMEN1KMT2AHPGD | |
| Fluorescein SCHEMBL1425151 | 0.80 | FTO (0.97) | FTOMAPTMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4348347-A2 | SYSTEM AND METHOD FOR HIGH RESOLUTION 3D NANOFABRICATION | Irradiant Technologies Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| WO-2022251546-A2 | SYSTEM AND METHOD FOR HIGH RESOLUTION 3D NANOFABRICATION | Irradiant Technologies Inc. (US) | 2022-12-01 | — | — | WO | claimed |
| US-20260044085-A1 | LINE SCANNING TEMPORALLY FOCUSED TWO-PHOTON LITHOGRAPHY SYSTEM | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2025235812-A1 | SYSTEMS AND METHODS FOR INTEGRATED FREE SPACE OPTICAL ELEMENTS AND DEVICES | IRRADIANT TECHNOLOGIES, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4594822-A1 | LINE SCANNING TEMPORALLY FOCUSED TWO-PHOTON LITHOGRAPHY SYSTEM | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024073400-A1 | LINE SCANNING TEMPORALLY FOCUSED TWO-PHOTON LITHOGRAPHY SYSTEM | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20220370630-A1 | TRANSMUCOSAL DELIVERY SYSTEM FOR PHARMACEUTICAL ACTIVE INGREDIENT TO SUBMUCOSAL TISSUE OF BLADDER | SEIKAGAKU CORPORATION (JP) | 2022-11-24 | — | — | US | disclosed |
| EP-4039279-A1 | TRANSMUCOSAL DELIVERY SYSTEM FOR MEDICINAL ACTIVE INGREDIENT TO SUBMUCOSA OF BLADDER | Seikagaku Corporation (JP) | 2022-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260044085-A1 | LINE SCANNING TEMPORALLY FOCUSED TWO-PHOTON LITHOGRAPHY SYSTEM | DVL3, DVL1, LOXL2 | FTO 3122/4885MAPT 470/4885MEN1 2881/4885 |
| US-20220370630-A1 | TRANSMUCOSAL DELIVERY SYSTEM FOR PHARMACEUTICAL ACTIVE INGREDIENT TO SUBMUCOSAL TISSUE OF BLADDER | PIGS, MMP7, CD44 | FTO 4793/4885MAPT 2519/4885MEN1 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.